Share chart Shattuck Labs, Inc.
Extended chart
Simple chart
About Shattuck Labs, Inc.
Shattuck Labs, Inc., биотехнологическая компания на клинической стадии, разрабатывает терапевтические средства для лечения рака и аутоиммунных заболеваний в Соединенных Штатах. Ведущим кандидатом на продукт компании является SL-172154, который находится в фазе 1 клинических испытаний для лечения рака яичников. Он также заключил соглашение о сотрудничестве с Takeda Pharmaceuticals для разработки SL-279252, который находится в стадии 1 клинических испытаний у пациентов с прогрессирующими солидными опухолями и лимфомой. Компания была основана в 2016 году со штаб-квартирой в Остине, штат Техас.Main settings
| IPO date | 2020-10-09 |
|---|---|
| ISIN | US82024L1035 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | link |
| Change price per day: | 0% (1.08) |
|---|---|
| Change price per week: | +2.86% (1.05) |
| Change price per month: | +28.88% (0.838) |
| Change price per 3 month: | -37.21% (1.72) |
| Change price per half year: | 0% (1.08) |
| Change price per year: | -85.58% (7.49) |
| Change price per 3 year: | -74.88% (4.3) |
| Change price per year to date: | -6.09% (1.15) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 10.74 | 1 |
| P/BV | 0.7713 | 9 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -60.18 | 0 |
| ROE, % | -67.23 | 0 |
| ROIC, % | -20.71 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.0444 | 10 |
| Debt/Ratio | 0.0374 | 10 |
| Debt/Equity | 0.1435 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | -42.21 | 0 |
| Yield Ebitda, % | 107.96 | 10 |
| Yield EPS, % | -35.41 | 0 |
Insider trading
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| FMR, LLC | 7 071 174 | 14.89 |
| Redmile Group, LLC | 5 619 914 | 11.84 |
| Prosight Management, LP | 2 782 797 | 5.86 |
| Adage Capital Partners GP L.L.C. | 1 752 705 | 3.69 |
| Franklin Resources, Inc. | 1 635 821 | 3.45 |
| Clark Estates Inc. (The) | 1 475 648 | 3.11 |
| Vanguard Group Inc | 1 317 066 | 2.77 |
| Point72 Asset Management, L.P. | 670 435 | 1.41 |
| Laurion Capital Management, LP | 661 038 | 1.39 |
| Maven Securities Limited | 633 876 | 1.34 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
|---|---|---|---|
| iShares Morningstar Small-Cap Growth ETF | 0.00651 | 595.05 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.00302 | 391.25 | 0.25 |
| 0.01 | 493.15 | 0.15 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Ms. Casi DeYoung | Chief Business Officer | 523.48k | 1971 (54 years) |
| Mr. Andrew R. Neill M.B.A. | Chief Financial Officer | N/A | 1986 (39 years) |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer | 567.4k | 1973 (52 years) |
| Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs | N/A | |
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, CEO & Director | 783.75k | 1980 (45 years) |
| Mr. Conor Richardson CPA | Vice President of Investor Relations | N/A | |
| Mr. George Fromm Ph.D. | Chief Scientific Officer of ARC Platform | N/A | |
| Mr. Suresh de Silva Ph.D. | Chief Scientific Officer of GADLEN Platform | N/A | |
| Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | N/A | 1975 (50 years) |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer | 1959 (66 years) |
About company
Address: United States, Austin, 1018 West 11th Street - Open in google maps, Open in yandex maps
Website: http://www.shattucklabs.com
Website: http://www.shattucklabs.com
